Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation.

about

Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation.

Item

http://www.wikidata.org/entity/Q38833534

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Optimizing outcomes for patien ...... eligible for transplantation.

@en

type

Item

label

Optimizing outcomes for patien ...... eligible for transplantation.

@en

prefLabel

Optimizing outcomes for patien ...... eligible for transplantation.

@en

P1476

Optimizing outcomes for patien ...... eligible for transplantation.

@en

P2093

C Touzeau

http://www.w3.org/2001/XMLSchema#string

P Moreau

http://www.w3.org/2001/XMLSchema#string

P2860

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

Lenalidomide after stem-cell transplantation for multiple myeloma

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies.

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

P2888

leusup.2013.4

P304

S15-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1038/LEUSUP.2013.4

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1043432146

http://www.w3.org/2001/XMLSchema#string

P698

27175256

http://www.w3.org/2001/XMLSchema#string

P932

4851188

http://www.w3.org/2001/XMLSchema#string